A new antitumor substance, BE-18591, produced by a streptomycete. I. Fermentation, isolation, physico-chemical and biological properties.
New antitumor substance, designated BE-18591, was isolated from the culture broth of a streptomycete, strain BA18591. The active principle was extracted from mycelium by methanol and purified by silica gel chromatography. BE-18591 inhibited the growth of MKN-45 human stomach cancer cell line as well as P388 cell line. In in vivo experiments, BE-18591 inhibited the growth of Ehrlich ascites tumor.BE-18591 showed antimicrobial activity against Gram-positive and some Gram-negative bacteria.
Kojiri
K
K
New Drug Discovery Research Laboratories, Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., Japan.
Nakajima
S
S
Suzuki
H
H
Okura
A
A
Suda
H
H
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000302:isolation & purification* / Q000378:metabolism / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D005285:Fermentation; D007941:Leukemia P388 / Q000188:drug therapy / Q000473:pathology; D009682:Magnetic Resonance Spectroscopy; D051379:Mice; D011758:Pyrroles / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology; D013302:Streptomyces / Q000737:chemistry / Q000378:metabolism*
D000903:Antibiotics, Antineoplastic; D011758:Pyrroles; C085612:BE 18591